SCHEMBL14837281

SCHEMBL14837281

O=C(Oc1ccc(C2COCCN2)cc1)C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 1/20 0.36
▸ KDM1A O60341 5/20 0.34
▸ PRKACA P17612 1/20 0.33
▸ PRKACG P22612 1/20 0.33
▸ PRKACB P22694 1/20 0.33
▸ METTL3 Q86U44 1/20 0.33
▸ S1PR4 O95977 2/20 0.31
▸ S1PR1 P21453 2/20 0.31
▸ S1PR3 Q99500 2/20 0.31
▸ S1PR5 Q9H228 2/20 0.31
▸ ELANE P08246 1/20 0.30
▸ ATR Q13535 1/20 0.30
▸ KIF11 P52732 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14829511 0.85 PRKACA (0.42) CTSKKDM1APRKACAPRKACGPRKACB
SCHEMBL14830112 0.82 CTSK (0.35) CTSKPRKACAPRKACGPRKACBMETTL3
Trifluoroacetic Acid SCHEMBL14837280 0.81 KDM1A (0.47) CTSKKDM1APRKACAPRKACGPRKACB
Trifluoroacetic Acid SCHEMBL14829650 0.81 KCNH2 (0.43) CTSKKDM1AMETTL3S1PR4S1PR1
SCHEMBL19580707 0.79 NISCH (0.40) KDM1APRKACAPRKACGPRKACB
SCHEMBL19580550 0.79 NISCH (0.40) KDM1APRKACAPRKACGPRKACB
Hydrochloric Acid SCHEMBL29650845 0.78 NISCH (0.39) KDM1APRKACAPRKACGPRKACB
Hydrochloric Acid SCHEMBL27174165 0.78 NISCH (0.39) KDM1APRKACAPRKACGPRKACB
Trifluoroacetic Acid SCHEMBL14829349 0.78 KDM1A (0.44) CTSKKDM1APRKACAPRKACGPRKACB
Trifluoroacetic Acid SCHEMBL14830111 0.77 CTSK (0.38) CTSKKDM1APRKACAPRKACGPRKACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2751088-B1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMA (US) 2016-04-13 — — EP disclosed
EP-2751088-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2014-07-09 — — EP disclosed
US-8765751-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-07-01 — — US disclosed
US-20130089624-A1 Compounds Useful as Inhibitors of ATR Kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-11 — — US disclosed
WO-2013049719-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130089624-A1 Compounds Useful as Inhibitors of ATR Kinase ATR, CHEK1, PLK1 CTSK 2008/4885KDM1A 2426/4885PRKACA 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback